<DOC>
	<DOCNO>NCT00002425</DOCNO>
	<brief_summary>To evaluate safety antiretroviral activity saquinavir soft gelatin capsule formulation ( SQV-SGC ) combination antiretroviral drug .</brief_summary>
	<brief_title>The Safety Effectiveness Saquinavir Soft Gelatin Capsules Combined With Other Anti-HIV Drugs</brief_title>
	<detailed_description>All patient receive SQV monotherapy combination antiretroviral drug choose investigator patient . ( This study provide SQV . ) Patients may choose another protease inhibitor ( PI ) part combination therapy ; furthermore , patient take PIs SQV must undergo 5-day washout period study-drug administration . Patients monitor adverse event change routine laboratory test , plasma viral load , CD4+ T cell level . Outcomes analyzed stratifying patient accord CD4+ T cell level prior history protease inhibitor .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Antiretroviral treatment PIs . Patients must : HIV infection . No prior experience PIs . ( Note : At least 75 percent patient must naive PIs . ) Exclusion Criteria Concurrent Medication : Excluded : PIs SQV . Prior Medication : Excluded : Any PIs ( see note General CriteriaInclusion ) .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 1996</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Saquinavir</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Dosage Forms</keyword>
	<keyword>Anti-HIV Agents</keyword>
</DOC>